Pediatric Myelodysplastic Syndrome

Zaina Inam; Miao Pan; Yaser Diab; Reuven Schore; Anant Vatsayan; Jinjun Cheng

doi:10.5858/arpa.2024-0164-RA

Pediatric Myelodysplastic Syndrome

Arch Pathol Lab Med. 2024 Oct 8. doi: 10.5858/arpa.2024-0164-RA. Online ahead of print.

Authors

Zaina Inam¹, Miao Pan^{2

3}, Yaser Diab^{1

4

5}, Reuven Schore^{1

6

5}, Anant Vatsayan^{1

7

5}, Jinjun Cheng^{1

2

3}

Affiliations

¹ From the Center for Cancer and Blood Disorders (Inam, Diab, Schore, Vatsayan, Cheng), Children's National Hospital, Washington, DC.
² the Divisions of Pathology and Laboratory Medicine (Pan, Cheng), Children's National Hospital, Washington, DC.
³ the departments of Pathology (Pan, Cheng), The George Washington University School of Medicine and Health Sciences, Washington, DC.
⁴ Hematology (Diab), Children's National Hospital, Washington, DC.
⁵ pediatrics (Diab, Schore, Vatsayan), The George Washington University School of Medicine and Health Sciences, Washington, DC.
⁶ Oncology (Schore), Children's National Hospital, Washington, DC.
⁷ Blood and Marrow Transplantation (Vatsayan), Children's National Hospital, Washington, DC.

PMID: 39379290
DOI: 10.5858/arpa.2024-0164-RA

Abstract

Context.—: Myelodysplastic syndromes (MDSs) are rare in children and have unique clinical manifestations and implications.

Objective.—: To review the clinical features, pathogenesis, and classification of pediatric MDS.

Data sources.—: Published literature and personal experience.

Conclusions.—: Pediatric MDS vastly differs from adult MDS. Evaluation for the presence of an underlying germline predisposition syndrome is critical for optimal classification and management. Because of the rarity of cases, resources to aid with the recognition, diagnosis, and management of pediatric MDS are limited, and multi-institutional collaborative studies are needed for the future.